Ian Battersby offers his thoughts on the EIS market in the run-up to the tax year-end, the potential impact of changes announced in the Budget and the proposals outlined in the much-anticipated Patient Capital Review
The waiting is over and, while the finer detail is still to emerge in some respects, we now know pretty much where we all stand. Realistically, I doubt there can be too many complaints about how ‘financing growth in innovative firms' is being positioned for the future - especially in the sense of tax-advantaged investments. Fears of sweeping changes, at least for now, appear unfounded and the consultation process seems to have largely taken on board the key issues raised by stakeholders from all parts of the tax-advantaged ecosystem. As a consequence, plans were unveiled in the Budget...
To continue reading this article...
Join Professional Adviser for free
- Unlimited access to real-time news, industry insights and market intelligence
- Stay ahead of the curve with spotlights on emerging trends and technologies
- Receive breaking news stories straight to your inbox in the daily newsletters
- Make smart business decisions with the latest developments in regulation, investing retirement and protection
- Members-only access to the editor’s weekly Friday commentary
- Be the first to hear about our events and awards programmes